IBDEI10L ; ; 01-FEB-2022
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,16499,1,4,0)
;;=4^D56.2
;;^UTILITY(U,$J,358.3,16499,2)
;;=^340496
;;^UTILITY(U,$J,358.3,16500,0)
;;=D75.9^^61^775^60
;;^UTILITY(U,$J,358.3,16500,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16500,1,3,0)
;;=3^Disease of Blood/Blood-Forming Organs,Unspec
;;^UTILITY(U,$J,358.3,16500,1,4,0)
;;=4^D75.9
;;^UTILITY(U,$J,358.3,16500,2)
;;=^5002393
;;^UTILITY(U,$J,358.3,16501,0)
;;=D59.0^^61^775^63
;;^UTILITY(U,$J,358.3,16501,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16501,1,3,0)
;;=3^Drug-Induced Autoimmune Hemolytic Anemia
;;^UTILITY(U,$J,358.3,16501,1,4,0)
;;=4^D59.0
;;^UTILITY(U,$J,358.3,16501,2)
;;=^5002323
;;^UTILITY(U,$J,358.3,16502,0)
;;=D59.2^^61^775^64
;;^UTILITY(U,$J,358.3,16502,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16502,1,3,0)
;;=3^Drug-Induced Nonautoimmune Hemolytic Anemia
;;^UTILITY(U,$J,358.3,16502,1,4,0)
;;=4^D59.2
;;^UTILITY(U,$J,358.3,16502,2)
;;=^5002325
;;^UTILITY(U,$J,358.3,16503,0)
;;=R59.9^^61^775^67
;;^UTILITY(U,$J,358.3,16503,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16503,1,3,0)
;;=3^Enlarged Lymph Nodes,Unspec
;;^UTILITY(U,$J,358.3,16503,1,4,0)
;;=4^R59.9
;;^UTILITY(U,$J,358.3,16503,2)
;;=^5019531
;;^UTILITY(U,$J,358.3,16504,0)
;;=D47.3^^61^775^68
;;^UTILITY(U,$J,358.3,16504,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16504,1,3,0)
;;=3^Essential Thrombocythemia
;;^UTILITY(U,$J,358.3,16504,1,4,0)
;;=4^D47.3
;;^UTILITY(U,$J,358.3,16504,2)
;;=^5002258
;;^UTILITY(U,$J,358.3,16505,0)
;;=C82.09^^61^775^69
;;^UTILITY(U,$J,358.3,16505,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16505,1,3,0)
;;=3^Follicular Lymphoma Grade I,Extranodal/Solid Organ Sites
;;^UTILITY(U,$J,358.3,16505,1,4,0)
;;=4^C82.09
;;^UTILITY(U,$J,358.3,16505,2)
;;=^5001470
;;^UTILITY(U,$J,358.3,16506,0)
;;=C82.00^^61^775^70
;;^UTILITY(U,$J,358.3,16506,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16506,1,3,0)
;;=3^Follicular Lymphoma Grade I,Unspec Site
;;^UTILITY(U,$J,358.3,16506,1,4,0)
;;=4^C82.00
;;^UTILITY(U,$J,358.3,16506,2)
;;=^5001461
;;^UTILITY(U,$J,358.3,16507,0)
;;=C82.19^^61^775^71
;;^UTILITY(U,$J,358.3,16507,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16507,1,3,0)
;;=3^Follicular Lymphoma Grade II,Extranodal/Solid Organ Sites
;;^UTILITY(U,$J,358.3,16507,1,4,0)
;;=4^C82.19
;;^UTILITY(U,$J,358.3,16507,2)
;;=^5001480
;;^UTILITY(U,$J,358.3,16508,0)
;;=C82.10^^61^775^72
;;^UTILITY(U,$J,358.3,16508,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16508,1,3,0)
;;=3^Follicular Lymphoma Grade II,Unspec Site
;;^UTILITY(U,$J,358.3,16508,1,4,0)
;;=4^C82.10
;;^UTILITY(U,$J,358.3,16508,2)
;;=^5001471
;;^UTILITY(U,$J,358.3,16509,0)
;;=C82.29^^61^775^73
;;^UTILITY(U,$J,358.3,16509,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16509,1,3,0)
;;=3^Follicular Lymphoma Grade III,Extranodal/Solid Organ Sites
;;^UTILITY(U,$J,358.3,16509,1,4,0)
;;=4^C82.29
;;^UTILITY(U,$J,358.3,16509,2)
;;=^5001490
;;^UTILITY(U,$J,358.3,16510,0)
;;=C82.20^^61^775^74
;;^UTILITY(U,$J,358.3,16510,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16510,1,3,0)
;;=3^Follicular Lymphoma Grade III,Unspec Site
;;^UTILITY(U,$J,358.3,16510,1,4,0)
;;=4^C82.20
;;^UTILITY(U,$J,358.3,16510,2)
;;=^5001481
;;^UTILITY(U,$J,358.3,16511,0)
;;=C82.39^^61^775^75
;;^UTILITY(U,$J,358.3,16511,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16511,1,3,0)
;;=3^Follicular Lymphoma Grade IIIa,Extranodal/Solid Organ Sites
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI10L 3809 printed Apr 09, 2024@20:47:53 Page 2
IBDEI10L ; ; 01-FEB-2022
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,16499,1,4,0)
+2 ;;=4^D56.2
+3 ;;^UTILITY(U,$J,358.3,16499,2)
+4 ;;=^340496
+5 ;;^UTILITY(U,$J,358.3,16500,0)
+6 ;;=D75.9^^61^775^60
+7 ;;^UTILITY(U,$J,358.3,16500,1,0)
+8 ;;=^358.31IA^4^2
+9 ;;^UTILITY(U,$J,358.3,16500,1,3,0)
+10 ;;=3^Disease of Blood/Blood-Forming Organs,Unspec
+11 ;;^UTILITY(U,$J,358.3,16500,1,4,0)
+12 ;;=4^D75.9
+13 ;;^UTILITY(U,$J,358.3,16500,2)
+14 ;;=^5002393
+15 ;;^UTILITY(U,$J,358.3,16501,0)
+16 ;;=D59.0^^61^775^63
+17 ;;^UTILITY(U,$J,358.3,16501,1,0)
+18 ;;=^358.31IA^4^2
+19 ;;^UTILITY(U,$J,358.3,16501,1,3,0)
+20 ;;=3^Drug-Induced Autoimmune Hemolytic Anemia
+21 ;;^UTILITY(U,$J,358.3,16501,1,4,0)
+22 ;;=4^D59.0
+23 ;;^UTILITY(U,$J,358.3,16501,2)
+24 ;;=^5002323
+25 ;;^UTILITY(U,$J,358.3,16502,0)
+26 ;;=D59.2^^61^775^64
+27 ;;^UTILITY(U,$J,358.3,16502,1,0)
+28 ;;=^358.31IA^4^2
+29 ;;^UTILITY(U,$J,358.3,16502,1,3,0)
+30 ;;=3^Drug-Induced Nonautoimmune Hemolytic Anemia
+31 ;;^UTILITY(U,$J,358.3,16502,1,4,0)
+32 ;;=4^D59.2
+33 ;;^UTILITY(U,$J,358.3,16502,2)
+34 ;;=^5002325
+35 ;;^UTILITY(U,$J,358.3,16503,0)
+36 ;;=R59.9^^61^775^67
+37 ;;^UTILITY(U,$J,358.3,16503,1,0)
+38 ;;=^358.31IA^4^2
+39 ;;^UTILITY(U,$J,358.3,16503,1,3,0)
+40 ;;=3^Enlarged Lymph Nodes,Unspec
+41 ;;^UTILITY(U,$J,358.3,16503,1,4,0)
+42 ;;=4^R59.9
+43 ;;^UTILITY(U,$J,358.3,16503,2)
+44 ;;=^5019531
+45 ;;^UTILITY(U,$J,358.3,16504,0)
+46 ;;=D47.3^^61^775^68
+47 ;;^UTILITY(U,$J,358.3,16504,1,0)
+48 ;;=^358.31IA^4^2
+49 ;;^UTILITY(U,$J,358.3,16504,1,3,0)
+50 ;;=3^Essential Thrombocythemia
+51 ;;^UTILITY(U,$J,358.3,16504,1,4,0)
+52 ;;=4^D47.3
+53 ;;^UTILITY(U,$J,358.3,16504,2)
+54 ;;=^5002258
+55 ;;^UTILITY(U,$J,358.3,16505,0)
+56 ;;=C82.09^^61^775^69
+57 ;;^UTILITY(U,$J,358.3,16505,1,0)
+58 ;;=^358.31IA^4^2
+59 ;;^UTILITY(U,$J,358.3,16505,1,3,0)
+60 ;;=3^Follicular Lymphoma Grade I,Extranodal/Solid Organ Sites
+61 ;;^UTILITY(U,$J,358.3,16505,1,4,0)
+62 ;;=4^C82.09
+63 ;;^UTILITY(U,$J,358.3,16505,2)
+64 ;;=^5001470
+65 ;;^UTILITY(U,$J,358.3,16506,0)
+66 ;;=C82.00^^61^775^70
+67 ;;^UTILITY(U,$J,358.3,16506,1,0)
+68 ;;=^358.31IA^4^2
+69 ;;^UTILITY(U,$J,358.3,16506,1,3,0)
+70 ;;=3^Follicular Lymphoma Grade I,Unspec Site
+71 ;;^UTILITY(U,$J,358.3,16506,1,4,0)
+72 ;;=4^C82.00
+73 ;;^UTILITY(U,$J,358.3,16506,2)
+74 ;;=^5001461
+75 ;;^UTILITY(U,$J,358.3,16507,0)
+76 ;;=C82.19^^61^775^71
+77 ;;^UTILITY(U,$J,358.3,16507,1,0)
+78 ;;=^358.31IA^4^2
+79 ;;^UTILITY(U,$J,358.3,16507,1,3,0)
+80 ;;=3^Follicular Lymphoma Grade II,Extranodal/Solid Organ Sites
+81 ;;^UTILITY(U,$J,358.3,16507,1,4,0)
+82 ;;=4^C82.19
+83 ;;^UTILITY(U,$J,358.3,16507,2)
+84 ;;=^5001480
+85 ;;^UTILITY(U,$J,358.3,16508,0)
+86 ;;=C82.10^^61^775^72
+87 ;;^UTILITY(U,$J,358.3,16508,1,0)
+88 ;;=^358.31IA^4^2
+89 ;;^UTILITY(U,$J,358.3,16508,1,3,0)
+90 ;;=3^Follicular Lymphoma Grade II,Unspec Site
+91 ;;^UTILITY(U,$J,358.3,16508,1,4,0)
+92 ;;=4^C82.10
+93 ;;^UTILITY(U,$J,358.3,16508,2)
+94 ;;=^5001471
+95 ;;^UTILITY(U,$J,358.3,16509,0)
+96 ;;=C82.29^^61^775^73
+97 ;;^UTILITY(U,$J,358.3,16509,1,0)
+98 ;;=^358.31IA^4^2
+99 ;;^UTILITY(U,$J,358.3,16509,1,3,0)
+100 ;;=3^Follicular Lymphoma Grade III,Extranodal/Solid Organ Sites
+101 ;;^UTILITY(U,$J,358.3,16509,1,4,0)
+102 ;;=4^C82.29
+103 ;;^UTILITY(U,$J,358.3,16509,2)
+104 ;;=^5001490
+105 ;;^UTILITY(U,$J,358.3,16510,0)
+106 ;;=C82.20^^61^775^74
+107 ;;^UTILITY(U,$J,358.3,16510,1,0)
+108 ;;=^358.31IA^4^2
+109 ;;^UTILITY(U,$J,358.3,16510,1,3,0)
+110 ;;=3^Follicular Lymphoma Grade III,Unspec Site
+111 ;;^UTILITY(U,$J,358.3,16510,1,4,0)
+112 ;;=4^C82.20
+113 ;;^UTILITY(U,$J,358.3,16510,2)
+114 ;;=^5001481
+115 ;;^UTILITY(U,$J,358.3,16511,0)
+116 ;;=C82.39^^61^775^75
+117 ;;^UTILITY(U,$J,358.3,16511,1,0)
+118 ;;=^358.31IA^4^2
+119 ;;^UTILITY(U,$J,358.3,16511,1,3,0)
+120 ;;=3^Follicular Lymphoma Grade IIIa,Extranodal/Solid Organ Sites
